Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
The Pharma Letter
Look back at pharma news in the week to April 3, 2020
It is admirable for a company like Lundbeck to have recognized the need to restock its drug development pipeline and turned to putting its cash pile to some serious…
FierceBiotech
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
Previously, EvaluatePharma’s researchers estimated that inclisiran sales could reach $1.529 billion by that time, but analysts would prefer to see that number top at…
FierceBiotech
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Analysts at EvaluatePharma have estimated the drug will be bringing in $2.4 billion in annual sales by 2024.
The Pharma Letter
Look back at pharma news in the week to March 13, 2020
Its 2022 forecast stands at an awesome $5.2 billion, EvaluatePharma computes, versus a little over $2 billion that it had in 2016 been thought capable of selling.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Handelszeitung
How is the pharmaceutical industry doing in the coronavirus stress test?
Market researcher Evaluate Pharma put the volume of deals for infectious diseases in the field of infectious diseases last year at $280 million last year.
Finanz und Wirtschaft
Pharmaceutical suppliers build in Switzerland
The market for service providers is expected to grow between 6 and 9% in the next few years, while the pharmaceutical market as a whole should grow by 5.9% annually…
Wall Street Journal
Insulin Giant Aims to Unlock Elusive Obesity-Drug Market
After Saxenda was approved in 2014, analysts forecast that its U.S. sales would top $250 million by 2020, according to a compilation of estimates by market-research firm…
FiercePharma
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
According to EvaluatePharma, drugs designated as orphan drugs will grow by 12.3% per year and top $242 billion in sales by 2024.
The Pharma Letter
Speedy review for PharmaMar's Zepsyre
By 2024, if approved, EvaluatePharma has said it expects the option to reach peak sales of up to $200 million.
